This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

José M. Azaña, MD; Ricardo F. de Misa, MD; Antonio Harto, MD; Antonio Ledo, MD; Agustín España, MD

Arch Dermatol. 1997;133(3):287-289.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

REPORT OF A CASE

A 64-year-old man presented with a 3-year history of severe pemphigus foliaceus. He had been treated with adequate doses of systemic corticosteroids, azathioprine sodium, intermittent methotrexate sodium, and cyclosporine. Maintenance treatment with prednisone (dose range, 40-60 mg/d) and azathioprine sodium (100 mg/d) was necessary to decrease new lesion formation. Nevertheless, he had 3 to 4 severe eruptions that required hospitalization (Figure 1 and Figure 2). Several adverse effects related to therapy were hypertension, cushingoid body habitus, and 1 episode of disseminated cutaneous herpetic infection.

THERAPEUTIC CHALLENGE

Systemic corticosteroids are the most useful drugs for the treatment of patients with pemphigus.¹ Corticosteroids and immunosuppressive drugs may induce clinical remission in most patients. However, the adverse effects of these drugs are currently the most common cause of death in patients with pemphigus.¹ Our patient had several adverse effects related to therapy and his disease was resistant . . . [Full Text PDF of this Article]

Author Affiliations
Universidad Alcalá de Henares, Madrid, Spain; Clínica Universitaria de Navarra, Navarra, Spain

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?